Sec Form 13G Filing - Brii Biosciences Limited filing for AN2 Therapeutics, Inc. (ANTX) - 2025-02-14

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  Note to Row 11: Calculated based on the 29,878,890 shares of common stock, $0.00001 par value per share, of AN2 Therapetics, Inc. (the "Issuer") outstanding as of November 6, 2024, as reported on the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024.


SCHEDULE 13G


 
Brii Biosciences Limited
 
Signature:/s/ Ankang Li
Name/Title:Ankang Li, Executive Director, Chief Strategy and Financial Officer
Date:02/14/2025
primary_doc.xml